Drug intelligence / Profile preview

NIDB-3101

Development stage: Preclinical
Lead developer: Discoveric Bio Alpha
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NIDB-3101 is a fully human bi- and multi-specific monoclonal antibody being developed for the treatment of Alzheimer's disease. It utilizes the κλ (Kappa Lambda) body platform to generate mixtures of bispecific antibodies that target key drivers implicated in Alzheimer's pathology. The drug is currently in preclinical development, with ongoing efforts focused on lead optimization and mechanistic modeling to predict pharmacokinetics and target occupancy in cerebrospinal fluid. The specific molecular targets remain undisclosed as of the latest updates. Development is led by discoveric bio alpha AG, with historical involvement from NovImmune SA (now Light Chain Bioscience)[1][3][4][5][7].

Beyond the preview

Go deeper on NIDB-3101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIDB-3101.

Explore the full profile